2022 ASCO前瞻 | 食管癌、胃癌及肝胆胰腺癌领域重磅研究一览

2022-05-13 22:37:10来源：医脉通阅读：11次

一年一度的全球肿瘤界盛会——美国临床肿瘤学会（ASCO）年会将于当地时间6月3日-7日召开。医脉通对食管癌、胃癌及肝胆胰腺癌领域的部分重磅研究进展进行了梳理。一起来看下吧！

临床科学研讨会

摘要号：4009

FOENIX-CCA2试验的最新结果：FGFR2融合/重排的肝内胆管癌（iCCA）中futibatinib的疗效和安全性。

标题：Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.

报告人：Lipika Goyal, MD

单位：Mass General Cancer Center, Harvard Medical School

摘要号：LBA4011

尼妥珠单抗联合吉西他滨对比吉西他滨单药治疗K-RAS野生型局部晚期或转移性胰腺癌：一项前瞻性、随机对照、双盲、多中心III期临床试验。

标题：Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

报告人：秦叔逵

单位：南京金陵医院

口头报告

摘要号：4001

K-Umbrella胃癌研究的首次报告：一项开放标签、多中心、随机、生物标志物相关的晚期胃癌（AGC）二线治疗试验。

标题：The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).

报告人：Sun Young Rha, MD, PhD

单位：Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine

摘要号：4003

随机、多中心、IIb期试验DANTE研究的中期结果：可切除食管胃腺癌患者围手术期接受阿替利珠单抗联合FLOT化疗vs单纯FLOT化疗的手术和病理结果以及病理缓解情况。

标题：Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.

报告人：Salah-Eddin Al-Batran, MD

单位：Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Frankfurt Am Main, Germany and Krankenhaus Nordwest, University Cancer Center Frankfurt

摘要号：4006

Trastuzumab deruxtecan（T-DXd; DS-8201）在 HER2阳性不可切除或复发性胆管癌（BTC）患者中的应用：一项由研究者发起的多中心II期试验（HERB试验）。

标题：Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

报告人：Akihiro Ohba, MD, MD

单位：National Cancer Center Hospital

摘要号：4008

随机III期试验CONKO-007研究的初步结果：对于不可切除的诱导化疗后局部晚期胰腺患者，放化疗与单纯化疗的对比。

标题：Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

报告人：Rainer Fietkau, MD

单位：Department of Radiation Oncology, Universitatsklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg

摘要号：4022

白蛋白紫杉醇/吉西他滨序贯mFOLFOX治疗一线转移性胰腺癌：SEQUENCE试验。

标题：Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial.

报告人：Alfredo Carrato, MD, PhD

单位：IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal

壁报讨论

摘要号：4013

应用FOLFOX术后辅助肝动脉灌注化疗（HAIC）以改善肝细胞癌微血管浸润患者的预后：一项前瞻性多中心III期随机对照临床试验。

标题：Postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX to improve outcomes of patients with hepatocellular carcinoma with microvascular invasion: A prospective multicenter, phase 3, randomized, controlled clinical trial.

报告人：李少华

单位：中山大学肿瘤防治中心

摘要号：4015

卡铂（CBP）+紫杉醇（PCL）（CP）术前放化疗或5-氟尿嘧啶（FU）+奥沙利铂（OX）（Fx）术前放化疗治疗食管癌或交界癌：一项随机II期临床试验。

标题：Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.

报告人：Antoine Adenis, MD, PhD

单位：Department of Medical Oncology, Montpellier Cancer Institute (ICM)

摘要号：4016

尼妥珠单抗联合同步放化疗对比单纯放化疗治疗不可切除的局部晚期食管鳞状细胞癌（ESCC）：前瞻性、随机对照、双盲、多中心III期临床试验（NXCEL1311研究）的中期分析。

标题：Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).

报告人：孟雪

单位：山东省肿瘤医院

摘要号：4017

评估靶向CLDN18.2的CAR-T细胞疗法（CT041）用于晚期胃/胃食管连接部腺癌患者安全性、耐受性和初步疗效的Ib/II期研究。

标题：Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).

报告人：齐长松

单位：北京大学肿瘤医院

摘要号：4019

吉西他滨联合顺铂（GemCis）辅助治疗与卡培他滨（CAP）辅助治疗在可切除淋巴结阳性肝外胆管癌（CCA）患者（pts）中的疗效对比：多中心、开放标签、随机II期研究STAMP。

标题：Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).

报告人：Changhoon Yoo, MD, PhD

单位：Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine

摘要号：4020

铂类联合依托泊苷（EP）方案对比替莫唑胺联合卡培他滨（CAPTEM）方案用于晚期G3非小细胞胃肠胰腺神经内分泌肿瘤（GEPNENs）患者的随机II期研究：ECOG-ACRIN EA2142。

标题：Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.

报告人：Jennifer Rachel Eads, MD

单位：University of Pennsylvania, Abramson Cancer Center

摘要号：4023

III期多中心随机研究AVENGER500：转移性腺癌患者一线治疗应用CPI-613联合mFOLFIRINOX（mFFX）对比FOLFIRINOX（FFX）的疗效评估。

标题：Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).

报告人：Philip Agop Philip, MD, PhD, FRCP

单位：Karmanos Cancer Center, Wayne State University, and SWOG

壁报展示

摘要号：4031

多西他赛联合奥沙利铂和S-1（DOS）对比奥沙利铂联合S-1（SOX）用于局部进展期胃或胃食管连接部腺癌围手术期治疗的研究：开放标签、随机II期MATCH研究。

标题：Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): An open-label, randomized, phase 2 study.

报告人：张文

单位：中国医学科学院北京协和医学院肿瘤医院肿瘤研究所（国家癌症中心）

摘要号：4040

评估KN026单药用于经治型晚期HER2阳性胃癌或胃食管连接部癌（GC/GEJC）患者的II期研究。

标题：A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC).

报告人：徐建明

单位：中国人民解放军总医院第五医学中心

摘要号：4052

一项评估白蛋白紫杉醇联合S-1（AS）对比卡培他滨联合奥沙利铂（CapeOX）治疗D2切除术后III期胃癌患者的随机、对照、多中心、开放标签研究。

标题：A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.

报告人：俞鹏飞

单位：浙江省肿瘤医院（中国科学院大学肿瘤医院）

摘要号：4071

立体定向放疗（SBRT）联合信迪利单抗治疗复发或寡转移性肝细胞癌（HCC）的II期研究。

标题：A phase II study of stereotactic body radiotherapy (SBRT) combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma (HCC).

报告人：陈一兴

单位：复旦大学附属中山医院放射肿瘤科

摘要号：4073

肝动脉灌注化疗（HAIC）联合信迪利单抗和贝伐珠单抗生物仿制药（IBI305）治疗初始不可切除的肝细胞癌（HCC）：一项前瞻性单臂II期临床试验。

标题：Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial.

报告人：Dongming Liu

单位：天津市肿瘤医院肿瘤研究所（天津医科大学肿瘤医院）

摘要号：4088

帕博利珠单抗（pembro）联合最佳支持治疗（BSC）对比安慰剂（PBO）联合BSC作为晚期肝细胞癌（HCC）亚洲患者二线治疗的健康相关生活质量（HRQoL）评估：III期KEYNOTE-394研究。

标题：Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

报告人：秦叔逵

单位：南京金陵医院

摘要号：4115

KN046（抗PD-L1/CTLA-4双特异性抗体）联合仑伐替尼治疗晚期不可切除或转移性肝细胞癌（HCC）的II期研究：疗效和安全性的更新结果。

标题：A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results.

报告人：邢宝才

单位：北京大学肿瘤医院

摘要号：TPS4172

AdvanTIG-206：抗TIGIT单克隆抗体（mAb）ociperlimab（BGB-A1217；OCI）联合替雷利珠单抗（TIS）联合BAT1706对比TIS联合BAT1706一线治疗晚期肝细胞癌（HCC）的疗效评估。

标题：AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).

报告人：樊嘉

单位：复旦大学附属中山医院

摘要号：TPS4183

II期试验daNIS-1：评估白蛋白紫杉醇/吉西他滨（NG）与抗TGF-β单克隆抗体NIS793联合或不联合PD-1抑制剂spartalizumab对比单纯NG方案用于转移性胰腺导管腺癌（mPDAC）患者一线治疗的研究。

标题：Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

报告人：Li-Yuan Bai, MD

单位：中国医药大学附设医院

摘要号：TPS4189

多中心、随机、双盲III期临床研究ENREACH-PDAC-01：KN046联合白蛋白紫杉醇和吉西他滨对比安慰剂联合白蛋白紫杉醇和吉西他滨在晚期胰腺癌中疗效和安全性的评估。

标题：A multicenter, randomized, double-blind phase III clinical study to evaluate the efficacy and safety of KN046 combined with nab-paclitaxel and gemcitabine versus placebo combined with nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer (ENREACH-PDAC-01).

报告人：金钢

单位：上海长海医院（海军军医大学第一附属医院）

备注：排名不分先后，按照摘要号进行排序

如有遗漏或任何建议，欢迎给我们留言~

参考来源：https://meetings.asco.org/meetings/2022-asco-annual-meeting